top of page
Home: About
OraGrowtH Trials

A phase 2 trial

for children with Pediatric Growth Hormone Deficiency

  • OraGrowtHTrials is a clinical trial program involving an oral investigational drug, called LUM-201, for Pediatric Growth Hormone Deficiency (PGHD).
     

  • This investigational drug for PGHD is an oral tablet.
     

  • It is different from the currently approved injections of recombinant human growth hormone (rhGH) for children with Growth Hormone Deficiency.  
     

  • The trial is currently enrolling participants aged 3-12.

210_Color_OraGrowtH_Logo_Trial-210_Color.png
What is the OraGrowtH210 Trial?

What is the OraGrowtH210 Trial?

OraGrowtH210 Trial is a research trial studying LUM-201(ibutamoren) as a potential oral treatment for Pediatric Growth Hormone Deficiency (PGHD) in pre-pubertal children.

 

OraGrowtH210 Trial is a Phase 2  randomized trial.
https://www.fda.gov/patients/drug-development-process/step-3-clinical-research#phases

 

The sponsor of this research study is Lumos Pharma and it is currently enrolling patients.

Icons Tablet.png

What is the Purpose of the Trial?

The purpose of the OraGrowtH210 Trial is to study the investigational drug in PGHD by:

  • Assessing different daily oral dosages to find an optimal dose of LUM-201. Some children will be randomly assigned to the current standard of care (rhGH injections)

 

  • Observing safety and tolerability

Icon measurement.png

Who Can Participate?

Pre-pubertal children, ages 3-12, diagnosed with PGHD, but have not started any Growth Hormone treatment, are invited to screen for trial eligibility.

 

If your child is eligible for the OraGrowtH210 Trial, the study will last 24 months and there will be clinic/office visits required.

 

The randomized trial will be open to 80 participants and the clinical sites are planned in the United States and other countries.

Icons Shot.png

Watch videos about the trial and LUM-201

Important Information – At the doses tested previously in the Merck Trials, LUM-201 was generally well-tolerated in children with the most commonly reported adverse events being digestive systems events, including appetite increase. Mild elevations in liver enzymes without accompanying changes in bilirubin were also reported.

Watch the video to learn about the OraGrowtH210 Trial 

Watch the video to learn about LUM-201 ibutamoren

Where can I participate?
Clincal Trials.gov listing
About the Sponsor

About the Sponsor

Lumos Pharma is passionately focused on developing therapeutics for rare diseases.

Rare disease patients and their caretakers inspire us to persevere and continue to advance the development of potential therapies to treat rare diseases. We are honored to work on collaborative projects such as increasing disease awareness, enabling better diagnostic modalities and access, and providing education and services to support patient and healthcare communities.

We are connected globally and proudly based in Austin, Texas and Ames, Iowa.

LOGO FINAL 2x (1).png
ADVOCACY CIRCLE.png
Home: Contact
bottom of page